These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36080198)

  • 1. Radionuclides for Targeted Therapy: Physical Properties.
    Stokke C; Kvassheim M; Blakkisrud J
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic radionuclides: production and decay property considerations.
    Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
    J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy?
    Widel M
    Neoplasma; 2017; 64(5):641-654. PubMed ID: 28592116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of radionuclides in therapy].
    Vucina J; Han R
    Med Pregl; 2001; 54(5-6):245-50. PubMed ID: 11759220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
    Abou-Jaoudé W; Dale R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The radiobiology of targeted radiotherapy.
    Wheldon TE; O'Donoghue JA
    Int J Radiat Biol; 1990 Jul; 58(1):1-21. PubMed ID: 1973428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
    Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
    Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
    DeNardo GL; Siantar CL; DeNardo SJ
    Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options to meet the future global demand of radionuclides for radionuclide therapy.
    Das T; Pillai MR
    Nucl Med Biol; 2013 Jan; 40(1):23-32. PubMed ID: 23116551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted radiotherapy using Auger electron emitters.
    O'Donoghue JA; Wheldon TE
    Phys Med Biol; 1996 Oct; 41(10):1973-92. PubMed ID: 8912375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-radiating radionuclides in cancer treatment, novel insight into promising approach.
    Asadian S; Mirzaei H; Kalantari BA; Davarpanah MR; Mohamadi M; Shpichka A; Nasehi L; Es HA; Timashev P; Najimi M; Gheibi N; Hassan M; Vosough M
    Pharmacol Res; 2020 Oct; 160():105070. PubMed ID: 32659429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Auger-electron spectra of radionuclides for therapy and diagnostics.
    Stepanek J; Larsson B; Weinreich R
    Acta Oncol; 1996; 35(7):863-8. PubMed ID: 9004764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
    Rao DV; Howell RW
    J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
    Armpilia CI; Dale RG; Coles IP; Jones B; Antipas V
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):378-85. PubMed ID: 12527051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides.
    Sadremomtaz A; Masoumi M
    J Med Imaging Radiat Sci; 2019 Jun; 50(2):272-279. PubMed ID: 31176435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted radionuclide therapy--an overview.
    Dash A; Knapp FF; Pillai MR
    Curr Radiopharm; 2013 Sep; 6(3):152-80. PubMed ID: 24059327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
    Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
    Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives.
    Chen Z; Nath R
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):825-34. PubMed ID: 12573770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.